Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
-0.33% $42.28
America/New_York / 8 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 589.08 mill |
EPS: | 1.220 |
P/E: | 34.66 |
Earnings Date: | May 21, 2024 |
SharesOutstanding: | 37.58 mill |
Avg Daily Volume: | 0.0435 mill |
RATING 2024-05-08 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Sell | |
P/E: | Buy | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
2.25x |
Company: PE 34.66 | sector: PE 15.43 |
PE RATIO: COMPANY / INDUSTRY |
---|
1.26x |
Company: PE 34.66 | industry: PE 27.41 |
DISCOUNTED CASH FLOW VALUE |
---|
$35.22 (-16.69%) $-7.06 |
Date: 2024-05-09 |
Expected Trading Range (DAY) |
---|
$ 41.99 - 42.58 ( +/- 0.70%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2011-01-18 | Sun Pharmaceutical Industries Ltd | Buy | 712 500 | Restricted Shares |
2011-01-18 | Sun Pharmaceutical Industries Ltd | Buy | 712 500 | Restricted Shares |
2011-01-18 | Sun Pharmaceutical Industries Ltd | Sell | 712 500 | Warrant (right to buy) |
2010-11-04 | Sun Pharmaceutical Industries Ltd | Buy | 5 159 765 | Ordinary Shares |
2010-11-01 | Franklin Resources Inc | Sell | 5 159 765 | Ordinary Shares |
INSIDER POWER |
---|
0.00 |
Last 84 transactions |
Buy: 16 575 249 | Sell: 25 681 902 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $42.28 (-0.33% ) |
Volume | 0.0193 mill |
Avg. Vol. | 0.0435 mill |
% of Avg. Vol | 44.37 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.